Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Nature Communications|September 14, 2022
Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6Chi monocytes and differentiation to pro-angiogenic myeloid cellsThi Tran, Jean-Remi Lavillegrand, Cedric Lereverend, et al.
International Journal of Cancer|July 30, 2024
Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapyCédric Lerévérend, Nour Kotaich, Lucille Cartier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2021
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)Thomas Cluzeau, Marie Sebert, Ramy Rahmé, et al.
Blood|July 7, 2021
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphomaBaptiste Eluard, Stéphanie Nuan-Aliman, Nathalie Faumont, et al.
BMC Cancer|July 24, 2013
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 casesJocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, et al.
Cancer Research|March 4, 2017
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical PracticeBernard Leroy, Mandy L Ballinger, Fanny Baran-Marszak, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Cell Metabolism|March 5, 2019
GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic InhibitorsJohanna Chiche, Julie Reverso-Meinietti, Annabelle Mouchotte, et al.
Nature Cancer|February 5, 2022
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitorsJana Jeschke, Evelyne Collignon, Clémence Al Wardi, et al.
Pageof 8